Press Release June 22, 2020

Mustang Bio Closes $40 Million Public Offering of Common Stock

Alston & Bird client Mustang Bio Inc., a clinical-stage biopharmaceutical company, has closed a public offering of common stock aimed at raising approximately $40 million.

The company will use the net proceeds from the offering for continued product development; potential in-license, acquisition, and development and commercialization of other pharmaceutical products; and general corporate purposes. 

Based in Worcester, MA, and listed on Nasdaq, Mustang focuses on acquiring, developing, and commercializing novel immunotherapies for cancers and rare genetic diseases.

Representing Mustang in the public offering is an Alston & Bird team led by partner Mark McElreath, senior associate Gerard Hart, and associate Joel Jung (Corporate) and partner Natalie Clayton and associate Ravi Shah (Intellectual Property).
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.